JP Morgan Chase
KPTI icon

JP Morgan Chase’s Karyopharm Therapeutics KPTI Stock Holding History

JP Morgan Chase’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-764,600
Closed -$5M – 7606
2025
Q3 		$5M Buy
764,600
+755,100
+7,948% +$4.06M ﹤0.01% 3364
2025
Q2 		$40.9K Hold
9,500
– – ﹤0.01% 5990
2025
Q1 		$35.5K Buy
+9,500
New +$81.1K ﹤0.01% 5984

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

JP Morgan Chase's KPTI Position: Q1 2026 in Review

JP Morgan Chase reduced its Karyopharm Therapeutics (KPTI) stake by 73% in Q1 2026, selling an estimated $9.68K and leaving 471 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6978.

JP Morgan Chase first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $6.85M in Q4 2019. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • JP Morgan Chase held 471 shares of Karyopharm Therapeutics worth $2.5K as of Q1 2026.
  • JP Morgan Chase sold 1,270 Karyopharm Therapeutics shares in Q1 2026, an estimated $9.68K.
  • Karyopharm Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6978 holding.
  • JP Morgan Chase first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • JP Morgan Chase's Karyopharm Therapeutics position peaked at $6.85M in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.